本文選題：延胡索顆粒 + 奧施康定��； 參考：《湖北中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的觀察延胡索顆粒聯(lián)合奧施康定治療腫瘤患者的癌性疼通的療效;研究其對(duì)癌性疼痛患者緩解情況及生活質(zhì)量改善情況,評(píng)價(jià)臨床使用的安全性;同時(shí)探討祖國醫(yī)學(xué)對(duì)癌性疼痛的認(rèn)識(shí)及治療策略,尋找二者在治療腫瘤相關(guān)性疼痛的結(jié)合點(diǎn)。方法選取來自于湖北省武漢市四醫(yī)院腫瘤科就診并且時(shí)間是在2016年1月至2016年10月期間的腫瘤相關(guān)性中度疼痛患者54例,均經(jīng)NRS評(píng)分為中度(4-7分)慢性癌痛的患者。將入組的病人用電腦隨機(jī)分為兩組,實(shí)驗(yàn)組(即延胡索顆粒組)31例,對(duì)照組(奧施康定組)23例。所有患者在性別、年齡、臨床分期、病理類型及體力狀況(Karnofsky評(píng)分)上均無明顯差異(P0.05)。對(duì)照組:予以初始穩(wěn)態(tài)劑量(疼痛評(píng)分48小時(shí)內(nèi)≤3分)奧施康定片20mg Q12h吞服,勿掰開嚼服、含服等。根據(jù)疼痛情況進(jìn)行滴定,連續(xù)用藥4周;觀察組:在治療組的基礎(chǔ)上,觀察組加用延胡索顆粒2袋/次,即1g/次Q12h,根據(jù)患者疼痛情況進(jìn)行滴定,連續(xù)用藥四周。治療前后檢查患者常規(guī)體檢指標(biāo),如血象、肝腎功能等;治療后對(duì)比兩組患者疼痛緩解率,不良反應(yīng)發(fā)生率及生活質(zhì)量改善情況。結(jié)果兩組患者在治療四周后,觀察組的疼痛控制率為74.19%,對(duì)照組的疼痛控制率為52.17%;兩組患者在疼痛緩解率上有顯著差異(P0.05);觀察組的不良反應(yīng)明顯低于對(duì)照組,觀察組不良反應(yīng)為54.84%,對(duì)照組為91.31%,二者在統(tǒng)計(jì)學(xué)上有顯著差異(P0.05)。在改善生活質(zhì)量方面,兩組療效相當(dāng),無明顯差異(P0.05)。結(jié)論延胡索顆粒聯(lián)合奧施康定能明顯改善中度癌痛患者的疼痛癥狀,能較好的減少暴發(fā)痛次數(shù)從而減少阿片類藥物的用量,能明顯減輕奧施康定引起的不良反應(yīng)。
[Abstract]:Objective to observe the curative effect of Yanhusuo granule combined with Oshkangding in the treatment of cancer patients with cancer pain, to study the relief of cancer pain and the improvement of quality of life, and to evaluate the safety of clinical use. At the same time, the understanding and treatment strategy of cancer pain in traditional Chinese medicine were discussed, and the combination of them in the treatment of cancer related pain was found. Methods from January 2016 to October 2016, 54 patients with moderate tumor-related pain were selected from the Department of Oncology, four Hospitals in Wuhan, Hubei Province. All patients were evaluated with NRS score of 4-7) with chronic cancer pain. The patients in the group were randomly divided into two groups: the experimental group (31 cases of Yanhusuo granule group) and the control group (Oshkangding group of 23 cases). There was no significant difference in sex, age, clinical stage, pathological type and physical status in all patients (P 0.05). Control group: the initial steady-state dose (pain score 鈮，

本文編號(hào)：1969936